Effect of tetravalent bispecific CD19XCD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells

International Journal of Cancer

Volumn 112, Issue 3, 2004, Pages 509-518

  Reusch, Uwe ^a   Le Gall, Fabrice ^a   Hensel, Manfred ^b   Moldenhauer, Gerhard ^c   Ho, Anthony D ^b   Little, Melvyn ^a   Kipriyanov, Sergey M ^a  

^a Affimed GmbH   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

B cell chronic lymphocytic leukemia; CD19; CD3; Immunotherapy; Tandem diabody

Indexed keywords

B7 ANTIGEN; CD19 ANTIBODY; CD19 ANTIGEN; CD3 ANTIBODY; CD3 ANTIGEN; CD86 ANTIGEN; RECOMBINANT ANTIBODY; TANDEM DIABODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LEUKEMIA; B LYMPHOCYTE; BLOOD SAMPLING; CELL CULTURE; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS LINKING; CYTOLYSIS; CYTOTOXICITY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TARGET CELL;

AGED; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD19; ANTIGENS, CD28; ANTIGENS, CD3; ANTIGENS, CD80; ANTIGENS, CD86; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOTHERAPY; LEUKEMIA, B-CELL, CHRONIC; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; RECOMBINANT PROTEINS; T-LYMPHOCYTES;

EID: 6344235689     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20417     Document Type: Article

References (53)

1. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995;333:1052-7.
2. Kay NE, Hamblin TJ, Jelinek DF, Dewald GW, Byrd JC, Farag S, Lucas M, Lin T. Chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program) 2002:193-213.
3. Mavromatis B, Cheson BD. Monoclonal antibody therapy of chronic lymphocytic leukemia. J Clin Oncol 2003;21:1874-81.
4. Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA, Santabarbara P, Wacker B, Brettman L. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002;20:3891-7.
5. Rodon P, Breton P, Courouble G. Treatment of pure red cell aplasia and autoimmune haemolytic anaemia in chronic lymphocytic leukaemia with Campath-1H. Eur J Haematol 2003;70:319-21.
6. Manshouri T, Do KA, Wang X, Giles FJ, O'Brien SM, Saffer H, Thomas D, Jilani I, Kantarjian HM, Keating MJ, Albitar M. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 2003;101:2507-13.
7. Huhn D, von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R, Knauf W, Riedel U, Hinke A, Srock S, Serke S, Peschel C, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001;98:1326-31.
8. van Spriel AB, van Ojik HH, van De Winkel JG. Immunotherapeutic perspective for bispecific antibodies. Immunol Today 2000;21:391-7.
9. Kipriyanov SM, Le Gall F. Recent advances in the generation of bispecific antibodies for tumor immunotherapy. Curr Opin Drug Discov Dev 2004;7:233-42.
10. Sieber T, Schoeler D, Ringel F, Pascu M, Schriever F. Selective internalization of monoclonal antibodies by B-cell chronic lymphocytic leukaemia cells. Br J Haematol 2003;121:458-61.
11. Anderson PM, Crist W, Hasz D, Carroll AJ, Myers DE, Uckun FM. G19.4(αCD3) x B43(αCD19) monoclonal antibody heteroconjugate triggers CD19 antigen-specific lysis of t(4;11) acute lymphoblastic leukemia cells by activated CD3 antigen-positive cytotoxic T cells. Blood 1992;80:2826-34.
12. Csóka M, Strauss G, Debatin K-M, Moldenhauer G. Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3 x CD19 bispecific antibody. Leukemia 1996;10:1765-72.
13. Kipriyanov SM, Moldenhauer G, Strauss G, Little M. Bispecific CD3xCD19 diabody for T cell-mediated lysis of malignant human B cells. Int J Cancer 1998;77:763-72.
14. Daniel PT, Kroidl A, Kopp J, Sturm I, Moldenhauer G, Dörken B, Pezzutto A. Immunotherapy of B-cell lymphoma with CD3x19 bispecific antibodies: costimulation via CD28 prevents "veto" apoptosis of antibody-targeted cytotoxic T cells. Blood 1998;92:4750-7.
15. Kipriyanov SM, Moldenhauer G, Schuhmacher J, Cochlovius B, Von der Lieth CW, Matys ER, Little M. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J Mol Biol 1999;293:41-56.
16. Löffler A, Kufer P, Lutterbuse R, Zettl F, Daniel PT, Schwenkenbecher JM, Riethmüller G, Dörken B, Bargou RC. A recombinant bispecific single-chain antibody, CD19xCD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 2000;95:2098-103.
17. Cochlovius B, Kipriyanov SM, Stassar MJJG, Schuhmacher J, Benner A, Moldenhauer G, Little M. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3xCD19 tandem diabody, and CD28 costimulation. Cancer Res 2000;60:4336-41.
18. Cochlovius B, Kipriyanov SM, Stassar MJJG, Christ O, Schuhmacher J, Strauss G, Moldenhauer G, Little M. Treatment of human B cell lymphoma xenografts with a CD3xCD19 diabody and T cells. J Immunol 2000;165:888-95.
19. Holliger P, Prospero T, Winter G. "Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 1993;90:6444-8.
20. Arndt MA, Krauss J, Kipriyanov SM, Pfreundschuh M, Little M. A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplanted human Hodgkin's tumors. Blood 1999;94:2562-8.
21. Kipriyanov SM, Moldenhauer G, Braunagel M, Reusch U, Cochlovius B, Le Gall F, Kouprianova OA, Von der Lieth CW, Little M. Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies. J Mol Biol 2003;330:99-111.
22. Kipriyanov SM, Cochlovius B, Schäfer HJ, Moldenhauer G, Bähre A, Le Gall F, Knackmuss S, Little M. Synergistic antitumor effect of bispecific CD19xCD3 and CD19xCD16 diabodies in a preclinical model of non-Hodgkin's lymphoma. J Immunol 2002;169:137-44.
23. Kipriyanov SM, Moldenhauer G, Martin ACR, Kupriyanova OA, Little M. Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity. Protein Eng 1997;10:445-53.
24. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F, Thomas M, Tchernia G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-206.
25. Kung PC, Goldstein G, Reinherz EL, Schlossman SF. Monoclonal antibodies defining distinctive human T cell surface antigens. Science 1979;206:347-9.
26. Pezzutto A, Dörken B, Rabinovitch PS, Ledbetter JA, Moldenhauer G, Clark EA. CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation. J Immunol 1987;138:2793-9.
27. Pohl C, Denfeld R, Renner C, Jung W, Bohlen H, Sahin U, Hombach A, van Lier R, Schwonzen M, Diehl V. CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma. Int J Cancer 1993;54:820-7.
28. Chambers CA, Allison JP. Costimulatory regulation of T cell function. Curr Opin Cell Biol 1999;11:203-10.
29. Jenkins MK, Taylor PS, Norton SD, Urdahl KB. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol 1991;147:2461-6.
30. Schriever F, Huhn D. New directions in the diagnosis and treatment of chronic lymphocytic leukaemia. Drugs 2003;63:953-69.
31. Bohlen H, Hopff T, Manzke O, Engert A, Kube D, Wickramanayake PD, Diehl V, Tesch H. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3xCD19 bispecific antibodies in combination with bivalent CD28 antibodies. Blood 1993;82:1803-12.
32. Grosse-Hovest L, Hartlapp I, Marwan W, Brem G, Rammensee HG, Jung G. A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing. Eur J Immunol 2003;33:1334-40.
33. Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood, 2004;103:4389-95.
34. Trambas CM, Griffiths GM. Delivering the kiss of death. Nat Immunol 2003;4:399-403.
35. + T cells in patients with B cell chronic lymphocytic leukemia kill via a perforin-mediated pathway. Haematologica 2004;89:435-43.
36. Daniel PT, Kroidl A, Cayeux S, Bargou R, Blankenstein T, Dörken B. Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis. J Immunol 1997;159:3808-15.
37. Jones RG, Elford AR, Parsons MJ, Wu L, Krawczyk CM, Yeh WC, Hakem R, Rottapel R, Woodgett JR, Ohashi PS. CD28-dependent activation of protein kinase B/Akt blocks Fas-mediated apoptosis by preventing death-inducing signaling complex assembly. J Exp Med 2002;196:335-48.
38. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992;71:1093-102.
39. Trentin L, Zambello R, Sancetta R, Facco M, Cerutti A, Perin A, Siviero M, Basso U, Bortolin M, Adami F, Agostini C, Semenzato G. B lymphocytes from patients with chronic lymphoproliferative disorders are equipped with different costimulatory molecules. Cancer Res 1997;57:4940-7.
40. Damle RN, Ghiotto F, Valetto A, Albesiano E, Fais F, Yan XJ, Sison CP, Allen SL, Kolitz J, Schulman P, Vinciguerra VP, Budde P, et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 2002;99:4087-93.
41. Frauwirth KA, Thompson CB. Activation and inhibition of lymphocytes by costimulation. J Clin Invest 2002;109:295-9.
42. Van den Hove LE, Van Gool SW, Vandenberghe P, Bakkus M, Thielemans K, Boogaerts MA, Ceuppens JL. CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules. Leukemia 1997;11:572-80.
43. Ghetie MA, Podar EM, Ilgen A, Gordon BE, Uhr JW, Vitetta ES. Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Proc Natl Acad Sci USA 1997;94:7509-14.
44. Ghetie MA, Ghetie V, Vitetta ES. Anti-CD19 antibodies inhibit the function of the P-gp pump in multidrug-resistant B lymphoma cells. Clin Cancer Res 1999;5:3920-47.
45. Kozono Y, Abe R, Kozono H, Kelly RG, Azuma T, Holers VM. Cross-linking CD21/CD35 or CD19 increases both B7-1 and B7-2 expression on murine splenic B cells. J Immunol 1998;160:1565-72.
46. Sansom DM, Manzotti CN, Zheng Y. What's the difference between CD80 and CD86? Trends Immunol 2003;24:314-9.
47. + T lymphocytes induced by CTLA-4 crosslinking. Proc Natl Acad Sci USA 1998;95:10083-8.
48. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003;100:8372-7.
49. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, Padera R, Jaklitsch MT, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003;100:4712-7.
50. Valitutti S, Muller S, Cella M, Padovan E, Lanzavecchia A. Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature 1995;375:148-51.
51. Löffler A, Gruen M, Wuchter C, Schriever F, Kufer P, Dreier T, Hanakam F, Baeuerle PA, Bommert K, Karawajew L, Dörken B, Bargou RC. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Leukemia 2003;17:900-9.
52. Dreier T, Lorenczewski G, BrandlC, Hoffmann P, Syring U, Hanakam F, Kufer P, Riethmüller G, Bargou R, Baeuerle PA. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 2002;100:690-7.
53. - bispecific single-chain antibody construct. J Immunol 2003;170:4397-402.